Analysis of local cholinergic tremor mechanisms following selective neurochemical lesions.
D000109:Acetylcholine / Q000009:adverse effects; D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects; D001921:Brain / Q000503:physiopathology; D002217:Carbachol / Q000009:adverse effects; D002415:Cats; D002800:Cholinesterase Inhibitors / Q000009:adverse effects*; D004195:Disease Models, Animal; D004298:Dopamine / Q000009:adverse effects; D004336:Drug Antagonism; D004357:Drug Synergism; D004837:Epinephrine / Q000009:adverse effects; D006426:Hemicholinium 3 / Q000009:adverse effects; D007531:Isoflurophate / Q000009:adverse effects; D007659:Ketones / Q000009:adverse effects; D008297:Male; D010091:Oximes / Q000009:adverse effects; D010424:Pentobarbital / Q000009:adverse effects; D010830:Physostigmine / Q000009:adverse effects; D011220:Pralidoxime Compounds / Q000009:adverse effects; D011955:Receptors, Drug / Q000187:drug effects; D012601:Scopolamine / Q000009:adverse effects; D014202:Tremor / Q000139:chemically induced* / Q000503:physiopathology
D002800:Cholinesterase Inhibitors; D007659:Ketones; D010091:Oximes; D011220:Pralidoxime Compounds; D011955:Receptors, Drug; D007531:Isoflurophate; D006426:Hemicholinium 3; D002217:Carbachol; D010830:Physostigmine; D012601:Scopolamine; D010424:Pentobarbital; D000109:Acetylcholine; D004298:Dopamine; D004837:Epinephrine